Navigation Links
Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
Date:5/14/2009

Top-line data indicate statistically significant improvement in ACR20 responses over placebo

PRINCETON, N.J., May 14 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that the MDX-1100 Phase 2 proof-of-concept trial in patients with active rheumatoid arthritis (RA) receiving methotrexate successfully met its primary endpoint. The top-line results from the recently completed 70-patient multi-center, randomized, double-blind, placebo-controlled Phase 2 trial indicated that when compared to placebo, three times the number of patients treated with 10 mg/kg of MDX-1100 every two weeks achieved at least a 20% improvement in RA signs and symptoms at 12 weeks, the primary endpoint of the study, as measured by the American College of Rheumatology (ACR) 20 measurement of response. These results were statistically significant when compared with placebo (p=0.0024). The antibody combination with methotrexate was generally safe and well-tolerated. Full results from this Phase 2 trial are planned to be presented at a future scientific meeting.

"We are greatly encouraged by this demonstration of efficacy from a well-designed and well-executed study," said Howard H. Pien, Chairman and CEO of Medarex. "These results show that by targeting the chemokine IP-10 with our MDX-1100 antibody, we may be able to offer a potentially important and novel treatment option for rheumatoid arthritis and potentially other inflammatory indications."

"Based on these positive results with a novel pro-inflammatory target, we are actively preparing for the next stage of clinical development for MDX-1100 in RA, including the potential for subcutaneous dosing," said Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We also look forward to exploring the broader potential of MDX-1100 in a range of i
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
11. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... February 9 Debiopharm Group,(Debiopharm), ... with,a focus on the development of prescription ... the signature of an exclusive licence agreement ... of Debio 025,(alisporivir), a selective, first-in-class cyclophilin ... (HCV) effect. The product is currently in ...
(Date:2/8/2010)... FRANKLIN LAKES, N.J. , Feb. 8 /PRNewswire/ ... and Company), announced today the launch of BD Microtainer® ... new product is designed to improve the safety, accuracy ... in patients with veins that can be difficult to ... elderly. The new BD Microtainer MAP product is also ...
(Date:2/8/2010)... Sagent Pharmaceuticals, Inc., a privately held ... received FDA approval of labetalol hydrochloride (HCl) injection, ... product will be available in two vial sizes ... mg per 40 mL, multi-dose vials.  According to ... Americans have hypertension, or high blood pressure.  IMS ...
Breaking Medicine Technology:Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3BD Launches New Device Designed to Improve Safety, Accuracy and Turnaround Time of Blood Collection in Patients with Fragile Veins 2Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP 2Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP 3New and Updated Online Tutorials for ArrayExpress Allen Brain Atlas and CleanEx from OpenHelix 54389 1New and Updated Online Tutorials for ArrayExpress Allen Brain Atlas and CleanEx from OpenHelix 54389 2New and Updated Online Tutorials for ArrayExpress Allen Brain Atlas and CleanEx from OpenHelix 54389 3Cancer Mortality Rates Experience Steady Decline 54386 1Cancer Mortality Rates Experience Steady Decline 54386 2Cancer Mortality Rates Experience Steady Decline 54386 3Cancer Mortality Rates Experience Steady Decline 54386 4APHL Chosen by PEPFAR to Develop Global Health Laboratory Systems 54384 1APHL Chosen by PEPFAR to Develop Global Health Laboratory Systems 54384 2
... May 31 Eli Lilly and Company announced today ... Lilly,s GEMZAR(R) (gemcitabine HCl for injection) to the current ... progression-free survival at three years for women with locally ... second most commonly diagnosed women,s cancer, and the second ...
... than double risk of cancer recurrence in tamoxifen treated ... drugs that reduce its effectiveness against breast cancerORLANDO, Fla., ... certain popular antidepressants frequently prescribed to women taking the ... of a breast cancer recurrence for those using both ...
Other Medicine Technology:Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 2Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 3Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 4Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 6New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 2New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 3New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 5
(Date:2/9/2010)... vitamin D begins in the womb, expert says, , , ... mothers who drink lots of milk and have a ... a much lower risk of developing multiple sclerosis later ... 35,794 U.S. nurses whose mothers provided information about their ... for 16 years, and 199 of them developed multiple ...
(Date:2/9/2010)... blood pressure restrict fetal growth, study finds, , , TUESDAY, ... bring into pregnancy can have lasting effects on your ... found that women who smoked, had high blood pressure ... babies that were smaller in the first trimester of ... , "Our study demonstrates that several maternal physical characteristics ...
(Date:2/9/2010)... Insurer-favored ,Cost Solution,: Selling Policies That Amount To ,A ... WASHINGTON , Feb. 9 Blue ... with its premium hikes of up to 39% in ... of questions from the White House and an investigation ... lawmakers should act to regulate health insurance premiums and ...
(Date:2/9/2010)... , Feb. 9 ... J. James Rohack , M.D., President, American ... ,, "The American Medical Association is ... Obama in the Let,s Move Campaign. ... have long worked to address obesity and ...
(Date:2/9/2010)... Institute and the Sanford-Burnham Medical Research Institute have ... owned member of the Roche group, and Roche, ... develop and market human monoclonal antibodies to treat ... viruses include the strains for the current seasonal ... a non-exclusive right to manufacture, develop and market ...
Breaking Medicine News(10 mins):Health News:Drinking Milk While Pregnant May Lower Kids' MS Risk 2Health News:Mom's Lifestyle in Early Pregnancy Affects Baby's Size 2Health News:Mom's Lifestyle in Early Pregnancy Affects Baby's Size 3Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 3
... of parents will be required by teenagers in Scotland who ... tattoo studios will also be subject to mandatory licensing// to ... to all those who are less than 16 years of ... the possibilities of blood borne diseases being transmitted through contaminated ...
... mother Bernadette Mimura, belonging to Ingleby Barwick Ingleby Barwick who ... disease//. She had refused life-saving treatment as it involved making ... the unborn baby, by the doctors. ,Being a ... a mild form of chemotherapy treatment with the object of ...
... to feel happy about the way he looks by just looking ... looks great he is convinced//. ,Women on the other ... difficult to satisfy them unless they are supplemented with actual results. ... was conducted by Kathleen Martin Ginis, associate professor of kinesiology at ...
... that moderate exercise has positive benefits on the hearts, ... studies in the last 10 to 20 years have ... people suffering from congestive heart failure. ,However, the ... to be statistically significant. ,In the new study ...
... on the Gulf of Carpentaria in Australia has triggered concerns ... virus//. ,However, the Australian Quarantine and Inspection Service ... they were sending out a team as a precautionary measure, ... a military operative has also started towards the island. "There's ...
... has been found to be effective in treatment of ... benefited from vitamin treatment as found by researchers from ... intervention wherein patients not responsive to steroid treatment after ... ,Professor Tak Lee, Director of the MRC-Asthma UK ...
Other Medicine News:Health News:Asthma an be treated with Vitamin supplement intervention 2
This product is for the lower body and uses a Convective Warming System which is both soft and comfortable. Constructed of 2-ply material consisting of polyethylene film inner layer and non-woven out...
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
CritiCool™ offers precise cooling to the programmed target temperature by applying temperature control algorithm....
Medicine Products: